Cite
HARVARD Citation
Cox, D. et al. (2022). Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study. Diabetes, obesity & metabolism. 24 (9), pp. 1770-1778. [Online].